**This article has been corrected:** The authors wish to make the readers aware of an error in the actin blot of [Fig. 5B](#F1){ref-type="fig"}. Actin levels were measured once in the six cell extracts used as input for the immunoprecipitations performed in [Figs. 5A](#F1){ref-type="fig"} and [5B](#F1){ref-type="fig"}. Results of the actin blot were then added to both [Figs. 5A](#F1){ref-type="fig"} and [5B](#F1){ref-type="fig"}. However, when the actin results were copied into [Fig. 5B](#F1){ref-type="fig"}, lanes were inadvertently shifted by one well. In the revised [figure 5B](#F1){ref-type="fig"}, shown below, the shifted actin blot is deleted. The correct actin blot for both [Figs. 5A](#F1){ref-type="fig"} and [5B](#F1){ref-type="fig"} is the one shown in [Fig. 5A](#F1){ref-type="fig"}. The authors declare that these corrections do not change the results or conclusions of this paper and apologize for any inconvenience caused by the error.
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![Rac1 inhibition abolishes IR-induced activation of both ATM and ATR signaling pathways.\
(**B**) To measure Chk1 and Chk2 activity, Chk1 and Chk2 were immunoprecipitated from the cell lysates using anti-Chk1 (G-4) and anti-Chk2 (B-4) antibodies respectively and assayed for relative kinase activity using recombinant Cdc25C protein as substrate. As controls, protein levels of ATR, ATM, Chk1 and Chk2 in the immunoprecipitates (IP-WB) as well as in the cell lysates (WB) were assessed by immunoblotting.](oncotarget-11-304-g001){#F1}
